Stratified medicine – The Future of Healthcare?

 

Click here to download the session presentations

 

Theme:  Healthcare
Time: 1415
Room: C

 

The burden of disease is increasing and is driving the cost of healthcare provision upwards.  Meanwhile the NHS is facing a static budget which, although ring fenced at present, is expected to deliver cost-savings over the next few years.  The pharmaceutical industry is under pressure to deliver more cost-effective medicines while facing a productivity crisis which has seen dramatic cost-cutting in that sector also.

 

Technology offers part of the solution to this conundrum, and the development of stratified medicines may provide benefits for payers, providers and patients.  It offers the prospect of tailoring treatments for patient groups, maximising effectiveness of treatments and minimising side effects. Success in this area could have a major impact on the way healthcare is provided and also create opportunity and wealth for UK industry.

 

Key benefits for attending this seminar:

• Learn about  the Technology Strategy Board approach to stratified medicine
• Learn about the potential business opportunities for companies in the stratified medicine arena
• Provide input into the development of a strategy in stratified medicines

This session is aimed at anyone who has an interest in future opportunities in healthcare. We invite businesses from different sectors with new ideas to contribute to providing solutions to problems in the space. We would encourage those business and sectors that are currently uninvolved in this topic, such as engineering firms, chemistry based companies, electronics and sensor technology companies and nanotechnology. The door is open to all.

 

This session will be facilitated by Zahid Latif, Head of Healthcare at the Technology Strategy Board and will comprise a short presentation followed by an expert panel discussion and  Q&A session.

The panel members are:
Richard Barker, Director General, ABPI
Declan Mulkeen, MRC
Doris-Ann Williams, Director General, BIVDA
Mark Bale, Dept. Of Health
James Peach, Cancer Research UK